Lantern Pharma is trading 5.49% up at $0.96 in pre-market, with trial advancement a plausible catalyst. - On October 7, Taiwan regulators and an institutional review board approved opening Part 2 of the Phase 2 HARMONIC trial of LP-300. - The lead site is now screening patients. - The rise runs counter to weak broader sentiment; no pre-market volume information was provided.